Take­da part­ners with Noile-Im­mune on next-gen CAR-T pipeline for sol­id tu­mors

Take­da is stak­ing out a new part­ner­ship it hopes will put it out front as new CAR-T drugs an­gle for a big break in­to sol­id tu­mors.

The phar­ma com­pa­ny is part­ner­ing with the start­up Noile-Im­mune Biotech, which is pur­su­ing what it says is a next-gen ap­proach to CAR-T.

No­var­tis just scored the pi­o­neer­ing reg­u­la­to­ry win in the field, fol­lowed close­ly by Kite Phar­ma. But these first ther­a­pies, which use reengi­neered T cells ex­tract­ed from pa­tients to at­tack hema­to­log­i­cal ma­lig­nan­cies, have been lim­it­ed in scope. Take­da and Tokyo-based Noile-Im­mune hope to use new tech de­vel­oped with re­searchers at Ya­m­aguchi Uni­ver­si­ty to over­come those lim­i­ta­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.